Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Resolvyx Pharmaceuticals, Inc.

Latest From Resolvyx Pharmaceuticals, Inc.

Plastic Surgery Market: Fat Grafting Grabs A Hefty Slice Of The Plastics Pie

Fat, fillers, and a "funnel" that may minimize a common cause of breast implant complications are among the hot topics in both aesthetic and reconstructive plastic surgery. Meanwhile, the acquisition by Actavis of Allergan – a leading player in the aesthetics market with BOTOX and breast implants – has the combined company poised for long-term double-digit revenue and earnings growth.

Medical Device North America

Warp Drive Bio revises senior management

Dr Gregory Verdine

Celtic finalises deal to move Resolvyx' dry eye treatment through Phase III

Celtic Therapeutic Holdings, the global private equity firm, has finalised an exclusive option deal announced in October with Resolvyx Pharmaceuticals to further develop a RX-10045, a late-stage topical eye-drop that has shown potential for treating dry eye syndrome and other ophthalmic conditions. Under the terms of the deal, Celtic has acquired and licensed worldwide rights to RX-10045 in exchange for up-front consideration, near-term milestone payments, and funding for 100% of future development costs (details of all of which were undisclosed).

Orthopedics Respiratory

Deals Shaping the Medical Industry (12/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals